From The Economic Times · Rica Bhattacharyya · · 40s
Zydus Lifesciences Growth Strategy
Zydus forecasts steady growth for five years as innovation matures.
In brief
Zydus forecasts steady growth for five years as innovation matures. Zydus Lifesciences expects decent revenue growth and improved profitability through specialty medicines and biologics by 2030. Originally reported by The Economic Times.
Zydus Transition
Zydus shifts from traditional pharma to patient-driven model.
Five-Year Growth
Zydus expects decent growth for next five years.
US Market Focus
US generics remain largest market with room for growth.
Saroglitazar Test
Saroglitazar aims for 18-20% US prescription share.
Innovation Matures
Profitability improves as innovation matures by 2030.
Oncology Expansion
Zydus leads global ADCs and precision diagnostics for cancer.
Future Strategy
Zydus targets 24% Ebitda by 2030 with specialty focus.
The big picture
Zydus Lifesciences expects decent revenue growth and improved profitability through specialty medicines and biologics by 2030.
